European regulators have recommended an update to the label of Novo Nordisk’s weight loss drug, Saxenda, to include information about the active ingredient’s ability to reduce cardiovascular risk.

Saxenda is a brand-name injectable solution prescribed for long-term weight management in adults and some children. It contains the active ingredient liraglutide. Saxenda is not safe to use during ...